# Efficacy of QAX576 in Asthma

> **NCT01130064** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 259 (actual)

## Conditions studied

- Asthma

## Interventions

- **BIOLOGICAL:** QAX576
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01130064
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-05
- **Primary completion:** 2012-04
- **Final completion:** 2012-04
- **Target enrollment:** 259 (ACTUAL)
- **Last updated:** 2020-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01130064

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01130064, "Efficacy of QAX576 in Asthma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01130064. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*